Bio-Rad Laboratories, Inc. (BIO) Launches New Digital PCR Systems in 2025

We recently compiled a list of 10 Most Undervalued Healthcare Stocks to Buy According to Analysts. Bio-Rad Laboratories, Inc. stands tenth on our list and is currently making waves for launching a new digital PCR system.

Bio-Rad Laboratories, Inc. (NYSE:BIO) is one of the most undervalued healthcare stocks. It is a global leader in life science research and clinical diagnostics and advanced its digital PCR capabilities in 2025 with the launch of four new Droplet Digital PCR (ddPCR) instruments, including the QX Continuum and QX700 series, acquired through its purchase of Stilla Technologies. These systems significantly expand the company’s ddPCR portfolio, now offering over 400,000 assays, and enhance applications in oncology, infectious disease, and genetic analysis through improved multiplexing, throughput, and workflow integration.

Supporting the growing field of gene therapy, Bio-Rad Laboratories, Inc. (NYSE:BIO) released ddPCR kits for accurate measurement of adeno-associated virus (AAV) vectors, enabling efficient viral titer and capsid integrity assessment. The company also extended its Vericheck kits to support additional viral serotypes for broader biotherapeutic research.

 Bio-Rad Laboratories, Inc. (BIO) Launches New Digital PCR Systems in 2025

15 States with the Best Healthcare in the US

The corporation’s other key product launches include the TrailBlazer Tag and StarBright Dye Label kits for antibody conjugation in flow cytometry and Western blotting, and new purification tools—Nuvia wPrime 2A resin and Foresight Pro columns, designed for scalable biopharma manufacturing.

Throughout 2025, Bio-Rad Laboratories, Inc. (NYSE:BIO) has remained actively engaged in global industry events, offering workshops on diagnostic innovation and showcasing its expanding technology portfolio for both clinical and research applications.

While we acknowledge the risk and potential of BIO as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than BIO and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.